Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) does about 217.19K shares in volume on a normal day but saw 448014 shares change hands in the recent trading day. The company now has a market cap of 1.08B USD. Its current market price is $10.78, marking an increase of 4.76% compared to the previous close of $10.29. The 52 week high reached by this stock is $12.45 whilst the lowest price level in 52 weeks is $5.15.
Centessa Pharmaceuticals plc ADR (CNTA) has a 20-day trading average at $9.53 and the current price is -13.41% off the 52-week high compared with 109.32% distance from its 52-week low. The 50-day simple moving average of the closing price is $9.12 and its 200-day simple moving average is $8.72. If we look at the stock’s price movements over the week, volatility stands at 6.11%, which decreases to 5.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.78 to suggest the stock is neutral.
The consensus objective for the share price is $14.17, suggesting that the stock has a potential upside of 23.92% over the period.
3 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 18, 2024 when Oppenheimer initiated the stock to “Outperform” and issued a price target of $14. Jefferies upgraded the stock to “Buy” from Hold on November 15, 2023 at a price target of $4-$11. Morgan Stanley upgraded its price target at $4-$8.
Centessa Pharmaceuticals plc ADR (CNTA) stock is up 14.32% over the week and 19.91% over the past month. Its price is 35.43% year-to-date and 46.67% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.26 above consensus estimates by 0.23. The company’s next earnings report forecasts estimating quarterly EPS at -0.39 and -1.65 for whole year.
To reach the target analysts have set, the stock logically needs to grow 23.92 percent from here.
The company has a return on investment of -46.08% and return on equity of -54.51%. The beta has a value of 1.37. Price to book ratio is 5.03 and price to sales ratio is 156.75.
